Memorial Sloan Kettering Cancer Center - Commack

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Colorectal cancer3 trials
• Metastatic breast cancer3 trials
• Bladder cancer2 trials
• Deep vein thrombosis and pulmonary embolism2 trials
• Mesothelioma2 trials
• Prostate cancer2 trials
• Triple-negative breast cancer2 trials
• Childhood cancers1 trial
• Chronic lymphocytic leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• and 5 more

Phase

• Phase 210 trials
• Phase 38 trials
• Phase 1/22 trials
• Phase 11 trial

Status

• Active, not recruiting9 trials
• Completed5 trials
• Recruiting5 trials
• Terminated3 trials
• Not yet recruiting1 trial

Lead sponsor

• Memorial Sloan Kettering Cancer Center8 trials
• Anthos Therapeutics, Inc.2 trials
• Genentech, Inc.2 trials
• Pfizer2 trials
• Taiho Oncology, Inc.2 trials
• and 7 more

Running trials

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

  Contact: Taiho Oncology, Inc.

• Recruiting

  A Study of Sacituzumab Govitecan in People With Mesothelioma

  NCT06477419· Phase 2· Memorial Sloan Kettering Cancer Center· Source

  Contact: Michael Offin, MD

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

  NCT05968326· Phase 2· Genentech, Inc.· Source

• Recruiting

  A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

  NCT05967689· Phase 2· Taiho Oncology, Inc.· Source

  Contact: Taiho Oncology, INC

• Active, not recruiting

  A Study of Rusfertide in Adults With Polycythemia Vera (PV)

  NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Pfizer· Source

• Recruiting

  Collection of Information to Better Understand Young Onset Colorectal Cancer

  NCT04489238· Memorial Sloan Kettering Cancer Center· Source

  Contact: Andrea Cercek, MD

• Active, not recruiting

  A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

  NCT04174196· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

  NCT03808337· Phase 2· Memorial Sloan Kettering Cancer Center· Source

  Contact: Amy Xu, MD, PhD

• Recruiting

  Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

  NCT03618550· Phase 2· Memorial Sloan Kettering Cancer Center· Source

  Contact: Alison Moskowitz, MD

• Active, not recruiting

  Olaparib In Metastatic Breast Cancer

  NCT03344965· Phase 2· Beth Israel Deaconess Medical Center· Source

• Active, not recruiting

  Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

  NCT02864992· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· Phase 3· Pfizer· Source

• Active, not recruiting

  RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Colorectal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

  NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source

• Terminated

  A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

  NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

  NCT04040231· Phase 1· Memorial Sloan Kettering Cancer Center· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Astellas Pharma Global Development, Inc.· Source

• Completed

  A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT02500407· Phase 1/2· Genentech, Inc.· Source

• Completed

  A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

  NCT02145871· Phase 3· Memorial Sloan Kettering Cancer Center· Source

• Completed

  Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

  NCT02025010· Phase 2· Dana-Farber Cancer Institute· Source

• Completed

  Quality of Life in Patients Undergoing Total Pelvic Exenteration

  NCT00597805· Memorial Sloan Kettering Cancer Center· Source